One daily tablet. Hair treatment out of sight.
One daily oral minoxidil tablet for people who want prescription hair care without a topical routine.
About 10 minutes. No charge unless your clinician approves.
The familiar hair molecule, from the inside.
Minoxidil is the active ingredient people know from topical hair-loss products. Oral treatment keeps the same molecule and changes the route completely: one tablet instead of a daily scalp application.
That route is the reason to consider the oral form.
Minoxidil began as a blood-pressure medication, which is why cardiovascular history matters. The molecule acts systemically, so blood pressure, heart history, swelling, and medication interactions remain part of the prescribing decision even when hair is the treatment goal.
For the right candidate, the practical advantage is obvious. No liquid, no drying time, no residue, no styling around an application. The treatment becomes one medication habit rather than a hair-care ritual.
One tablet replaces a daily topical routine. Cardiovascular screening and the months-long treatment horizon stay part of the same decision.
Read the evidence →For people who quit the routine before they quit the idea.
The Topical-Fatigued
You know minoxidil. What you dislike is the liquid, the drying time, the residue, and having to organize hair styling around treatment. You want to ask whether the oral route is medically reasonable.
The Adherence Realist
You have learned that a theoretically perfect regimen is useless if you stop doing it. One tablet fits your life better than a scalp application you already know you will resent.
The Cardiovascular-Screened Patient
You understand that oral minoxidil is not a casual route swap. Blood pressure and cardiovascular history belong in the decision, and you want someone qualified making that call.
Oral minoxidil is FDA-approved for high blood pressure and is prescribed off-label at low doses for hair loss. A licensed provider reviews your cardiovascular history and determines candidacy, and results vary.
This might not be the right fit if:
- Known cardiovascular conditions, without provider clearance
- Uncontrolled low or fluctuating blood pressure
- Known hypersensitivity to minoxidil
- Pregnancy or breastfeeding, unless specifically cleared by your provider
- A tendency toward fluid retention or swelling that has not been evaluated
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Minoxidil, prescribed with care.
FDA-approved generic medication. Prescribed by a licensed provider after clinical review.
- Oral minoxidil prescribed for hair loss after clinician review
- Cardiovascular and blood-pressure history reviewed before prescribing
- Schedule set by your provider
- Continued use is required to maintain treatment benefit
- Tolerability and response followed through ongoing care
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Beauty & Skin.
Glutathione
Antioxidant defense, under clinical direction.
Compounded injectable glutathione for clinician-guided antioxidant defense beyond the supplement aisle.
GHK-Cu Copper Peptide Cream
Prescription strength. Every percentage disclosed.
Prescription-compounded GHK-Cu cream in disclosed 2% and 4% strengths, not a mystery cosmetic complex.
Men's Oral Hair Compound
One capsule instead of a shelf of products.
One compounded capsule brings minoxidil, finasteride, biotin, and vitamin E into a single clinician-guided routine.
What the research shows
Oral minoxidil did not beat topical minoxidil on hair density at the scalp or vertex.
The detail
In a 24-week double-blind, double-dummy randomized clinical trial in 90 men aged 18 to 55 with androgenetic alopecia, of whom 68 completed, oral minoxidil 5 mg once daily did not demonstrate superiority over topical minoxidil 5 percent twice daily for terminal hair density at the frontal scalp or the vertex; photographic analysis favored oral minoxidil at the vertex by 24 percent, 95 percent confidence interval 0 to 48, and hypertrichosis was reported in 49 percent of the oral group.1
In women, oral and topical minoxidil both increased hair diameter and density, with no difference between them.
The detail
In a 9-month triple-blind randomized clinical trial in 72 women with female pattern hair loss, oral minoxidil 0.25 mg daily and topical minoxidil 2 percent each significantly increased average hair diameter and hair density from their own baselines, and the difference between the two treatments was not statistically significant.2
Pooled trials found no difference in hair density, but more hypertrichosis on the oral form.
The detail
In a meta-analysis of four randomized clinical trials covering 279 patients with androgenetic alopecia followed for 24 to 39 weeks, oral and topical minoxidil did not differ in hair density or hair diameter, while hypertrichosis was significantly more common with the oral form, risk ratio 2.01, 95 percent confidence interval 1.18 to 3.41.3
Hypertrichosis was the most frequent effect; no life-threatening effects were observed.
The detail
In a retrospective multicenter study of 1404 patients treated with low-dose oral minoxidil for at least three months for any type of alopecia, the most frequent adverse effect was hypertrichosis at 15.1 percent, systemic effects included lightheadedness at 1.7 percent, fluid retention at 1.3 percent and tachycardia at 0.9 percent, 1.2 percent of patients stopped the drug because of adverse effects, and no life-threatening adverse effects were observed. The study had no control group.4
The topical comparator itself beat placebo on hair count and scalp coverage ratings.
The detail
The comparator in those trials is itself well supported: in a 48-week double-blind, placebo-controlled, randomized multicenter trial in 393 men aged 18 to 49, topical minoxidil 5 percent was superior to both topical minoxidil 2 percent and placebo vehicle for change in nonvellus hair count and for patient and investigator ratings of scalp coverage.5
What it does not show
Hair loss is an off-label use; the safety database was built at blood-pressure doses.
The detail
The molecule is FDA-approved; this use of it is not. The approved labeling for minoxidil tablets covers hypertension that is symptomatic or associated with target organ damage and not manageable with a diuretic plus two other antihypertensive drugs, and it carries a boxed warning about pericardial effusion progressing to tamponade and about exacerbation of angina. Hair loss is an off-label use, and the labeled safety database was built at blood-pressure doses rather than the much lower doses used for hair.6
No randomized trial has compared oral minoxidil with an inactive control.
The detail
No randomized trial has compared oral minoxidil with an inactive control for pattern hair loss. The randomized comparisons place it against topical minoxidil in double-dummy designs, so what they establish is that the oral route is not clearly better or worse than the topical one, not the size of the effect against no treatment at all.123
Nothing published covers years of continuous use at hair-loss doses.
The detail
The randomized follow-up runs 24 to 39 weeks and the largest safety dataset is a retrospective chart review with no control group. Nothing published establishes efficacy or cardiovascular safety across years of continuous use at hair-loss doses, which is the horizon on which this treatment is actually taken.34
Nothing here shows the oral route grows more hair than the topical route.
- Penha MA, Miot HA, Kasprzak M, Muller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a… JAMA Dermatol. 2024.
- Vahabi-Amlashi S, et al. A randomized clinical trial on therapeutic effects of 0.25 mg oral… Dermatol Ther. 2021.
- Sobral MVS, et al. Efficacy and safety of oral minoxidil versus topical solution in… Int J Dermatol. 2025.
- Vano-Galvan S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of… J Am Acad Dermatol. 2021.
- Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical… J Am Acad Dermatol. 2002.
- FDA-approved prescribing information, minoxidil tablets USP (oral), Par Health USA LLC, label published June 2026.DailyMed
The FDA-approved labeling for oral minoxidil covers its use as a blood-pressure medication and carries a boxed warning about fluid collecting around the heart, which can progress to tamponade, and about angina becoming worse.
Do not use if you have
- Pheochromocytoma
Serious risks
- Fluid retention with swelling or rapid weight gain
- A faster heart rate and lightheadedness
Commonly reported
- The effect people report most often: hair growing where they did not want it, on the face, arms or body
- The labeling describes that change appearing within three to six weeks of starting and taking one to six months to fade after stopping
Your provider reviews cardiovascular history, blood pressure and current medications closely. The molecule is FDA-approved and this use of it for hair is not, which is exactly why the decision sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Off-label prescribing means an FDA-approved medication is used for a purpose outside its approved indication. Clinicians prescribe oral minoxidil for hair loss after weighing the published evidence, cardiovascular history, dose, and alternatives. That status is one reason the decision belongs with a licensed provider.
Oral minoxidil has systemic cardiovascular effects because it is a blood-pressure medication. Whether it is appropriate at the dose your clinician is considering depends on your blood pressure, cardiovascular history, medications, and other factors. That screening is why the oral route belongs in prescription care.
After clinician approval, the prescription moves to pharmacy fulfillment. Any time, before your renewal date. No phone calls required.
Hair treatment is evaluated over months, not days, and response varies. Continued use matters, but your clinician reviews the trend rather than promising a particular visible result by a fixed date.